ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Join our measuringhero Jay on the innovation tour

Experience our latest innovation from the Control fair.

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

From powder to implant

Quality assurance for additively manufactured implants.

Anna Törner: “My quantified life”

“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...

The Future of Swedish & Danish Life Science (2026)

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”

Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previou...

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Radioactive tracer to measure effect of drug towards Crohn’s disease

A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn's disease. That is the belief of Mari...

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

One System, Three Contrasting Techniques

ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.

Carl Zeiss Meditec achieves revenue growth and stable operating profit

Further recovery in order entry compared to prior year.

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).